Patents by Inventor Timothy C. Scott
Timothy C. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210299055Abstract: The present invention contemplates a method of treating a solid cancerous tumor in a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of a halogenated xanthene (HX), the lactone thereof, a pharmaceutically acceptable salt, or a C1-C4 alkyl or aromatic ester thereof (collectively an HX compound) to that mammalian subject, and liquid and solid pharmaceutical compositions for administering the HX compound. In addition, a method of inhibiting the growth of a GI tract carcinoma of a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of an HX compound, as well as solid and liquid pharmaceutical compositions therefor.Type: ApplicationFiled: March 26, 2021Publication date: September 30, 2021Applicants: Provectus Pharmatech, Inc., Governors of the University of CalgaryInventors: Eric A. WACHTER, Dominic RODRIGUES, Edward V. PERSHING, Bruce HOROWITZ, Timothy C. SCOTT, H. Craig DEES, Aru NARENDRAN
-
Patent number: 8974363Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.Type: GrantFiled: November 8, 2007Date of Patent: March 10, 2015Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher
-
Patent number: 8557298Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: December 6, 2007Date of Patent: October 15, 2013Assignee: Provectus Pharmatech, Inc.Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Patent number: 8470296Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: GrantFiled: March 8, 2007Date of Patent: June 25, 2013Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20110097280Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: ApplicationFiled: December 30, 2010Publication date: April 28, 2011Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7863047Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: April 25, 2008Date of Patent: January 4, 2011Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20100076246Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: ApplicationFiled: August 19, 2009Publication date: March 25, 2010Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7648695Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: July 6, 2001Date of Patent: January 19, 2010Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott
-
Publication number: 20090117199Abstract: A method for the treatment of cancer, particularly a metastatic melanoma or a neoplastic lesion, the method comprising intralesional administration of a hydrophilic vehicle comprising 4,5,6,7-Tetrachloro-2?,4?,5?,7?-tetraiodofluorescein, or a physiologically acceptable salt thereof, at a concentration of about 0.1 w/v % up to about 20 w/v % and an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chlorine, a phosphate and a nitrate, wherein the electrolyte is at a concentration of between about 0.1 w/v % and about 2 w/v % and the pH of the solution between about 4 to about 10.Type: ApplicationFiled: December 5, 2008Publication date: May 7, 2009Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Publication number: 20080311035Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.Type: ApplicationFiled: August 19, 2008Publication date: December 18, 2008Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Patent number: 7427389Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.Type: GrantFiled: February 3, 2005Date of Patent: September 23, 2008Assignee: Provectus Pharmatech, Inc.Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Publication number: 20080207746Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: ApplicationFiled: April 25, 2008Publication date: August 28, 2008Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7402299Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: November 30, 2004Date of Patent: July 22, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7390668Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: March 6, 2001Date of Patent: June 24, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Publication number: 20080118567Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: ApplicationFiled: December 6, 2007Publication date: May 22, 2008Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Publication number: 20080118578Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.Type: ApplicationFiled: November 8, 2007Publication date: May 22, 2008Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher
-
Patent number: 7338652Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.Type: GrantFiled: February 3, 2005Date of Patent: March 4, 2008Assignee: Provectus Pharmatech, Inc.Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
-
Patent number: 6991776Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: GrantFiled: December 30, 2002Date of Patent: January 31, 2006Assignee: Xantech Pharmaceuticals, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 6986740Abstract: New contrast agents for ultrasound imaging and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal.Type: GrantFiled: December 9, 2002Date of Patent: January 17, 2006Assignee: Xantech Pharmaceuticals, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter
-
Publication number: 20030167006Abstract: New contrast agents for ultrasound imaging and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal.Type: ApplicationFiled: December 9, 2002Publication date: September 4, 2003Applicant: Xantech Pharmaceuticals, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachler